Earnings release
Page 1
1/22 Press Release Ad hoc announcement pursuant to article 53 LR Kaiseraugst (Switzerland), Maastricht (Netherlands), July 30, 2026 dsm-firmenich reports H1 2026 results Good LFL sales growth and sequential margin improvement through first half Highlights • Good like-for-like (LFL) sales growth of 5% in H1 2026, with 6% in Q2 • Adjusted EBITDA margin improved sequentially, with positive momentum into second half • Continued improvement in adjusted gross operating free cash flow • 2026-2028 action plan, aimed at accelerating financial performance, introduced at March 2026 CMD, fully on track • Successful dual listing of shares on SIX Swiss Exchange as of May 21 • €500 million share buyback program progressing well • Outlook unchanged: 2026 targets underpinned by good H1 delivery CEO comments “We achieved good volume-led LFL growth in the first six months of the year across all businesses, demonstrating the resilience and quality of our portfolio and the consistent delivery on our operational priorities amid a dynamic global macroeconomic environment. We expect full-year LFL sales growth to be at the higher end of our 2026 target of 2-4%. We are delivering on the action plan outlined at our 2026 Capital Markets Day, focused on accelerating top-line growth, margin expansion, and maintaining disciplined cash and capital management. These initiatives will drive a further sequential improvement to deliver an around 20% adjusted EBITDA margin in 2026. We are also executing our cost savings and restructuring program, to provide a strong foundation to achieve a further step-up in margin in 2027.” Dimitri de Vreeze, CEO Group Performance – Continuing Operations The company delivered good, volume-led sales growth across all businesses in the first half, owing to improving business conditions, contributions from revenue synergies, and higher win rates on customer briefs. Following 4% LFL sales growth in Q1, business conditions in Q2 2026 continued to be solid, resulting in 6% LFL sales growth. June saw a strong acceleration, owing to positive customer sentiment on easing Middle East concerns. The Adjusted EBITDA margin of 19.5% in Q2, reflects a 40 bps sequential improvement versus Q1. Versus the prior year period, the margin remained stable reflecting a negative impact of 70 bps from foreign exchange effects. On a LFL basis, Adjusted EBITDA was up 10% in Q2, and up 7% in the first half versus prior year. Core EPS increased by 14% in H1 2026 versus prior year period, reaching €1.84. Adjusted Gross Operating Free Cash Flow of 7% in H1 2026 improved versus the prior year period. With typically stronger cash flow performance in the second half of the year, the company expects to deliver on its full-year adjusted gross operating cash-to-sales ratio target of 11-12%. in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Sales 4,664 4,643 5 2,388 2,303 6 Adj. EBITDA 900 906 7 466 446 10 Adj. EBITDA margin (%) 19.3 19.5 19.5 19.4 Net profit from continuing operations 225 197 Net profit (total Group) 221 541
Page 2
2/22 Outlook 2026 unchanged: Fully on track with 2026 Strategic Action Plan The company expects Continuing Operations for the full-year 2026 to deliver: • Like-for-Like (LFL) sales growth: 2-4% • Adjusted EBITDA margin: around 20% • Cash conversion: Adjusted Gross Operating Free Cash Flow to Sales of 11-12% Underpinned by good H1 delivery, the company expects full-year LFL sales growth to be at the higher end of its 2026 target of 2-4%. This outlook assumes that, also in the second half, the conflict in the Middle East will have a limited impact. The company will address cost inflation through a range of initiatives including a cost savings and restructuring program, and pricing actions. Key figures and indicators – Continuing operations in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Net sales 4,664 4,643 5 2,388 2,303 6 P&B 1,948 1,919 7 981 945 7 TTH 1,634 1,629 4 843 802 6 HNC¹ 1,035 1,042 4 538 528 4 Corporate¹ 47 53 26 28 Adj. EBITDA 900 906 7 466 446 10 P&B 424 426 6 211 207 6 TTH 321 335 3 170 165 8 HNC 206 196 15 110 99 19 Corporate (51) (51) (25) (25) Adj. EBITDA margin (%) 19.3 19.5 19.5 19.4 P&B 21.8 22.2 21.5 21.9 TTH 19.6 20.6 20.2 20.6 HNC 19.9 18.8 20.4 18.8 Adj. EBIT 435 450 . Core adj. EBIT 664 677 Core adj. net profit 465 441 . Average number of shares (x millions) 250.2 263.5 Core adj. EPS 1.84 1.61 . (Avg.) core capital employed 11,480 11,909 Core adj. ROCE (%) 11.6 11.4 . Operating working capital 2,667 2,662 Net debt 4,424 2,459² 1 2025 figure restated for comparative purposes 2 Refers to Total Group, including Discontinued Operations
Page 3
3/22 Cost savings and restructuring program Earlier this year, at its Capital Markets Day, the company outlined a clear action plan focused on disciplined execution to accelerate financial performance. This plan is designed to deliver a structural improvement of approximately 1% in Adjusted EBITDA margin by 2027. This restructuring program (including the stranded cost elimination program from the Animal Nutrition & Health transaction) could lead to a reduction of about 1,000 positions over the next 18-24 months, in close consultation with relevant works councils. The company has fully deployed the program and expects €100 million in cost savings, and anticipates an exceptional cost of approximately €100 million. Strategic ambitions dsm-firmenich operates through three unique and complementary Business Units: Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care. These businesses are supported by clear strategic choices, a simplified operating model, and a strong focus on customer-driven innovation. The strategic ambition is to grow the three businesses by leveraging a unique combination of science, creativity, and customer intimacy, while anchoring performance through operational excellence, disciplined capital allocation, cost saving programs, and consistent commercial practices across the Group. Having successfully completed the group-wide transformation, the focus is on accelerating performance within the three business units. Looking ahead, the priority is to accelerate execution in 2026–2027 to drive growth and synergies, expand EBITDA margins, and improve cash conversion, underpinned by normalized capital expenditure, tighter working capital management, and greater cost discipline. The materials from the 2026 Capital Markets Day are available here. Swiss listing In addition to its listing on Euronext Amsterdam, dsm-firmenich established a dual listing of the company’s ordinary shares on SIX Swiss Exchange on May 21, 2026. This Swiss listing benefits dsm-firmenich and its shareholders by strengthening alignment with dsm-firmenich’s Swiss heritage and domicile, broadening access to Swiss and international equity investors, and also resulting in the inclusion in relevant Swiss equity indices. Share buyback program The company started a share repurchase program on March 12, 2026 to repurchase ordinary shares for a total amount of €540 million, of which €500 million to reduce its issued capital, and €40 million to cover commitments under the Group’s share-based compensation plans. On July 24, around 62% of the program had been executed. On February 26, 2026, following the completion of its €1 billion share buyback program in 2025, the company cancelled 12,049,441 shares. As a result, the total number of issued shares was reduced by approximately 4.5%, from 265,676,388 to 253,626,947 shares.
Page 4
4/22 Business Unit Review Perfumery & Beauty Q2 2026 Perfumery & Beauty delivered a LFL sales growth of 7%, fully volume driven, on a continued good business momentum with strong month of June. Fine Fragrances as well as Consumer Fragrances delivered double-digit LFL growth from strong market demand, supported by higher win rates of customer briefs. The Ingredients segment was stable. The Adjusted EBITDA margin was 21.5%, reflecting a 40 bps negative foreign exchange effect and some one-off operational costs, versus the prior year period. On a LFL basis, Adjusted EBITDA was up 6% in Q2 versus the prior year period. H1 2026 Perfumery & Beauty delivered a strong, volume-driven, 7% LFL sales growth in the first half. Fine Fragrances delivered double- digit LFL sales growth, with Consumer Fragrances recording high single-digit sales growth. Ingredients achieved low single-digit growth, across fragrance and beauty & care ingredients. The Adjusted EBITDA margin was 21.8%, reflecting some one-off operational costs and a negative foreign exchange effect of 20 bps versus the prior year period. On a LFL basis, Adjusted EBITDA was up 6% in H1 versus the prior year period. in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Sales 1,948 1,919 7 981 945 7 Adj. EBITDA 424 426 6 211 207 6 Adj. EBITDA margin (%) 21.8 22.2 21.5 21.9 Taste, Texture & Health Q2 2026 The business unit saw solid business conditions, reporting a 6% LFL growth, up from 2% in Q1. Revenue synergies contributed about 2% to sales growth, while Bovaer had a positive impact of 1%. Growth was driven by both Taste and Ingredients Solutions, and across all regions, with a strong recovery in Latin America, and business conditions picking up in Europe and North America, the latter benefiting from the FIFA World Cup. The Beverages and Baking segments delivered good performance, while continued high demand in the Dairy segment drove good growth in enzymes and cultures. The Adjusted EBITDA margin increased sequentially from 19.1% in Q1, to 20.2% in Q2. Versus prior year, the margin reflects a 70 bps negative impact from foreign exchange. On a LFL basis, Adjusted EBITDA was up 8% in Q2 versus the prior year period. H1 2026 Taste, Texture & Health delivered a volume-led LFL growth of 4%, with an improving momentum across its businesses, supported by revenue synergies of 1.5%. The Adjusted EBITDA margin was 19.6%, with a 60 bps adverse foreign exchange impact and some higher costs. On a LFL basis, Adjusted EBITDA was up 3% in H1 versus the prior year period. in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Sales 1,634 1,629 4 843 802 6 Adj. EBITDA 321 335 3 170 165 8 Adj. EBITDA margin (%) 19.6 20.6 20.2 20.6
Page 5
5/22 Health, Nutrition & Care Q2 2026 Health, Nutrition & Care delivered 4% volume-driven sales growth, in line with the first quarter. This consistent performance was driven by Early Life Nutrition, led by ongoing strong demand for HMOs and favorable conditions for ARA, as well as good growth in Biomedical. Dietary Supplements and i-Health continued to experience cautious consumer behavior, especially in North America. The Adjusted EBITDA margin increased to 20.4%, with strong growth in high-margin products, despite a negative foreign exchange effect of 110 bps. On a LFL basis, Adjusted EBITDA was up 19% in Q2 versus the prior year period. H1 2026 Health, Nutrition & Health delivered 4% LFL sales growth, led by strong performance in Early Life Nutrition, and good performance in Biomedical. The Adjusted EBITDA margin was 19.9%, continuing its consistent, gradual improvement, despite a negative foreign exchange effect of 90 bps. On a LFL basis, Adjusted EBITDA was up 15% in H1, versus the prior year period. in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Sales¹ 1,035 1,042 4 538 528 4 Adj. EBITDA 206 196 15 110 99 19 Adj. EBITDA margin (%) 19.9 18.8 20.4 18.8 1 2025 figure restated for comparative purposes. Corporate activities in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Sales¹ 47 53 (11) 26 28 (7) Adj. EBITDA (51) (51) - (25) (25) - 1 2025 figure restated for comparative purposes. Cash Flow and Working Capital Adjusted gross operating free cash flow in the first half saw a good step-up versus the prior year period, supported by lower working capital. With a typically stronger cash flow performance in the second half of the year, the company expects to deliver on its full-year adjusted gross operating cash-to-sales ratio target of 11% to 12%. H1 2026 H1 2025 in € millions Continuing operations Continuing operations Adj. gross operating free cash flow 320 79 Sales to cash conversion % 6.9 1.7 . Operating working capital (OWC) 2,667 2,662 OWC as % of sales - end of period 27.9 28.9 Total working capital (WC) 2,081 2,219 Total WC as % of sales - end of period 21.8 24.1
Page 6
6/22 Continuing operations Sales drivers in € millions H1 2026 H1 2025 % LFL % Volume % Price % FX % M&A % Change Sales 4,664 4,643 5 5 - (4) (1) 0 P&B 1,948 1,919 7 7 - (4) (1) 2 TTH 1,634 1,629 4 4 - (4) - 0 HNC¹ 1,035 1,042 4 3 1 (5) - (1) Corporate¹ 47 53 (11) 1 2025 figure restated for comparative purposes. in € millions Q2 2026 Q2 2025 % LFL % Volume % Price % FX % M&A % Change Sales 2,388 2,303 6 6 - (1) (1) 4 P&B 981 945 7 7 - (1) (2) 4 TTH 843 802 6 6 - (1) - 5 HNC¹ 538 528 4 3 1 (2) - 2 Corporate¹ 26 28 (7) 1 2025 figure restated for comparative purposes. Adj. EBITDA drivers in € millions H1 2026 H1 2025 % LFL % FX % M&A % Change Adj. EBITDA 900 906 7 (7) (1) (1) P&B 424 426 6 (5) (1) (0) TTH 321 335 3 (7) - (4) HNC 206 196 15 (10) - 5 Corporate (51) (51) in € millions Q2 2026 Q2 2025 % LFL % FX % M&A % Change Adj. EBITDA 466 446 10 (5) (1) 4 P&B 211 207 6 (3) (1) 2 TTH 170 165 8 (5) - 3 HNC 110 99 19 (8) - 11 Corporate (25) (25) - Adj. EBITDA margin in % H1 2026 H1 2025 Adj. EBITDA margin (%) 19.3 19.5 P&B 21.8 22.2 TTH 19.6 20.6 HNC 19.9 18.8 in % Q2 2026 Q2 2025 Adj. EBITDA margin (%) 19.5 19.4 P&B 21.5 21.9 TTH 20.2 20.6 HNC 20.4 18.8
Page 7
7/22 Discontinued Operations Further to the announced divestment of the ANH activities to CVC Capital Partners in February 2026, the assets and liabilities of the divested business have been classified as Assets Held for Sale, and the financial results of the ANH activities have been reclassified to Discontinued Operations. Following the expected weak start to the year due to low vitamin prices in the first quarter, business conditions improved in Q2. Higher prices, ongoing efficiency initiatives, and higher demand, led to an improvement in profitability in the second quarter. H1 results were substantially lower versus the prior year period, which included an exceptional contribution from temporary high vitamin prices due to a force majeure situation in the industry. Discontinued Operations are expected to deliver a positive cash contribution in 2026. in € millions H1 2026 H1 2025 % LFL % Volume % Price % FX % M&A % Change Sales 1,518 1,867 (12) 1 (13) (1) (6) (19) Adj. EBITDA 67 354 (77) (5) 1 (81) Adj. EBITDA margin (%) 4.4 19.0 in € millions Q2 2026 Q2 2025 % LFL % Volume % Price % FX % M&A % Change Sales 796 933 (11) (1) (10) 1 (5) (15) Adj. EBITDA 44 164 (68) (5) - (73) Adj. EBITDA margin (%) 5.5 17.6 Total Group in € millions H1 2026 H1 2025 % LFL Q2 2026 Q2 2025 % LFL Sales 6,182 6,510 - 3,184 3,236 1 Adj. EBITDA 967 1,260 (17) 510 610 (11) Adj. EBITDA margin (%) 15.6 19.4 16.0 18.9 Alternative Performance Measures (APMs) The policy on Alternative Performance Measures (APMs) and a reconciliation between the APMs and the most directly reconcilable IFRS metric can be found in Note 2 to the Condensed consolidated interim financial statements. The main APM adjustments to operating profit (EBIT) in the first half of 2026 are listed below: • Restructuring costs of €22 million, mainly related to the cost of current savings and restructuring programs. • Other costs of €42 million, mainly related to litigation and claims.
Page 8
8/22 Definitions This press release includes information that is presented in accordance with IFRS as issued by the International Accounting Standard Board and alternative performance measures (APMs). Please refer to the section below for the definitions as applied. Alternative Performance Measures (APMs) In monitoring the financial performance of dsm-firmenich, management uses certain Alternative performance measures (APMs) not defined by IFRS. These APMs should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. APMs do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. To arrive at the Alternative Performance Measures (APMs) Adjusted EBITDA, Adjusted EBIT, and Adjusted net profit, adjustments are made for material items of income and expense arising from circumstances such as acquisitions and divestments, restructuring, impairments and other events (i.e., APM adjustments). Other APM adjusting events include site closure costs, environmental cleaning, litigation settlements or other non-operational (contractual) arrangements. Other than items related to acquisition and integration costs incurred in the first year from the acquisition date (including non-recurring inventory value adjustments) as well as adjustments due to previously recognized APM adjusting events, the threshold is €10 million. The APMs used throughout this press release are: Like-for-like (LFL) Like-for-like (LFL) represents the change in performance measures excluding the impact of acquisitions, divestments, and currency impacts. Earnings before interest, tax, depreciation and amortization (EBITDA) EBITDA is defined as IFRS metric operating profit plus depreciation, amortization, and impairments. Adjusted earnings before interest, tax, depreciation and amortization (Adj. EBITDA) Adjusted EBITDA is the EBITDA adjusted for material items of profit or loss, as defined under ‘APM adjustments’. EBITDA margin EBITDA margin is EBITDA expressed as a percentage of net sales. Adjusted EBITDA margin (Adj. EBITDA margin) Adjusted EBITDA margin is adjusted EBITDA expressed as a percentage of net sales. Adjusted operating profit (Adj. EBIT) Adjusted operating profit (Adj. EBIT) is the IFRS metric operating profit adjusted for material items of profit or loss, as defined under ‘APM adjustments’. Core adjusted EBIT (Core adj. EBIT) Core adjusted EBIT is calculated as the IFRS metric operating profit adjusted for material items of profit or loss, as defined under ‘APM adjustments’, and adjusted for the impact of the amortization of intangible assets recognized through purchase price allocations (PPA). Adjusted net profit (Adj. net profit) Adjusted net profit is the IFRS metric net profit adjusted for material items of profit or loss, as defined under ‘APM adjustments’. Core adjusted net profit (Core adj. net profit) Core adjusted net profit is the IFRS metric net profit (from continuing operations) adjusted for material items of profit or loss, as defined under ‘APM adjustments’, and adjusted for the impact of the amortization of intangible assets recognized through purchase price allocations (PPA) as well as the PPA impact on financial income and expense. Adjusted gross operating free cash flow (AGOFCF) Adjusted gross operating free cash flow (AGOFCF) is defined as the IFRS metric operating profit plus depreciation, amortization, and impairments, adjusted for material items of profit or loss, as defined under ‘APM adjustments’, corrected for changes in the working capital, minus capital expenditures. This metric is based on continuing operations.
Page 9
9/22 Sales to cash conversion % Sales to cash conversion % is the adjusted gross operating free cash flow (AGOFCF) as a percentage of net sales. Adjusted earnings per share (Adj. EPS) Adjusted earnings per share (Adjusted EPS) is calculated as the net profit available to holders of ordinary shares adjusted for material items of profit or loss, as defined under ‘APM adjustments’, divided by the average number of ordinary shares outstanding. Core adjusted earnings per share (Core adj. EPS) Core adjusted earnings per share (Core adjusted EPS) is calculated as the net profit (from continuing operations) available to holders of ordinary shares adjusted for material items of profit or loss, as defined under ‘APM adjustments’, adjusted for the impact of the amortization of intangible assets recognized through purchase price allocations (PPA) as well as the PPA impact on financial income and expense, divided by the average number of ordinary shares outstanding. Capital employed Capital employed is the total of the carrying amount of intangible assets and property, plant and equipment, inventories, trade receivables and other receivables, less trade payables, other current liabilities, investment grants and customer funding. Average capital employed is calculated as the average of the capital employed at the end of the preceding five quarters, including the current quarter. Core capital employed Core capital employed is defined as capital employed, adjusted for the impact of the Firmenich purchase price allocation (PPA). Average core capital employed is calculated as the average of the core capital employed at the end of the preceding five quarters, including the current quarter. Return on capital employed (ROCE) Return on capital employed (ROCE) is the adjusted operating profit (from continuing operations) as a percentage of average capital employed. Core adjusted return on capital employed (Core adj. ROCE) Core adjusted return on capital employed (Core adj. ROCE) is core adjusted EBIT as a percentage of average core capital employed. Operating working capital (OWC) The total of inventories and trade receivables, less trade payables. Operating working capital (OWC) as % of sales Operating working capital as % of sales is the operating working capital as a percentage of annualized fourth-quarter net sales. Working capital (WC) The total of inventories and current receivables, less current payables. Working capital (WC) as % of sales Working capital as % of sales is the working capital as a percentage of annualized fourth-quarter net sales. Capital expenditures (CAPEX) Capital expenditures include all investments in intangible assets and property, plant and equipment. Net debt Net debt is the total of current and non-current borrowings less cash and cash equivalents, current investments and the net position of derivatives.
Page 10
10/22 Statement of the Board of Directors This document represents dsm-firmenich’s half yearly report containing the management report as well as the condensed consolidated interim financial statements for the purpose of the Dutch Act on Financial Supervision (Wet Financieel Toezicht), section 5:25d. Per the Dutch Decree on Transparency for issuing entities subject to the Dutch Act on Financial Supervision (Besluit Transparantie uitgevende instellingen Wft) article 10, the Directors declare that, to the best of their knowledge: • The condensed consolidated interim financial statements have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board • The interim management report gives a fair review of important events during the first six months of the financial year that impacted the Company’s business. Thomas Leysen, Chairman of the Board of Directors Dimitri de Vreeze, Chief Executive Officer
Page 11
11/22 Financial calendar November 4, 2026 - publication of dsm-firmenich Q3 2026 trading update February 18, 2027 – publication of dsm-firmenich FY 2026 results March 24, 2027 – AGM, Kaiseraugst (CH) Additional information Today dsm-firmenich will hold a webcast for investors and analysts at 9:00 am CEST. Details on how to access this call can be found on www.dsm-firmenich.com Note for editors The full text of the press release is available here. The presentation to investors is available here. For more information Media relations Robin Roothans tel. +41 (0)79 280 03 96 e-mail media@dsm-firmenich.com Investor relations Dave Huizing tel. +31 (0)88 425 7306 e-mail investors@dsm-firmenich.com About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on Euronext Amsterdam (DSFIR) and SIX Swiss Exchange (DSFIR), with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com About Continuing Operations Continuing Operations reflects the results of dsm-firmenich, following the announced divestment of Animal Nutrition & Health (ANH) activities to CVC Capital Partners. The assets and liabilities of the divested businesses have been classified as Assets Held for Sale in accordance with IFRS 5, and the results of the divested businesses have been reclassified to Discontinued Operations. Forward-looking statements This press release may contain forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.
Page 12
12/22 Condensed consolidated interim financial statements H1 2026 Condensed consolidated interim income statement H1 2026 H1 2025 Continuing operations Net sales 4,664 4,643 Gross profit 1,866 1,848 Operating profit 370 383 Financial income and expense (66) (69) Profit before tax 304 314 Income tax expense (63) (67) Share of net profit of associates and joint ventures (16) (50) Net profit from continuing operations 225 197 Net profit from discontinued operations (4) 344 Net profit for the period 221 541 Attributable to: - Holders of shares 212 510 - Non-controlling interests 9 31 . Earnings per share (EPS) total (in €): - Basic EPS 0.85 1.94 . Earnings per share (EPS) continuing operations (in €): - Basic EPS 0.88 0.69 Condensed consolidated interim statement of comprehensive income in € millions H1 2026 H1 2025 Net profit for the period 221 541 Other comprehensive income Remeasurements of defined benefit liability 58 (29) Change in fair value reserve (2) (4) Exchange differences on translation of foreign operations relating to non-controlling interests 5 (11) Related tax (12) 3 Items that will not be reclassified to profit or loss 49 (41) . Exchange differences on translation of foreign operations 250 (600) Change in hedging reserve (39) 110 Equity accounted investees - share of other comprehensive income - (2) Related tax 6 (19) Items that may subsequently be reclassified to profit or loss 217 (511) . Total comprehensive income for the period, net of tax 487 (11)
Page 13
13/22 Condensed consolidated interim statement of changes in equity x € millions Share capital Share premium Treasury shares Other reserves Retained earnings Shareholders' equity Non- contr. interests Total Equity Balance at January 1, 2025 3 11,313 (147) 710 10,632 22,511 186 22,697 Total comprehensive income - - - (515) 484 (31) 20 (11) Dividend - (379) - - (280) (659) (57) (716) Stock options and share units granted - - - 18 - 18 - 18 Stock options and share units vested / canceled - - - (17) 17 - - - Reissued shares - - 11 - (10) 1 - 1 Repurchase own shares - - (363) - - (363) - (363) Acquisition of NCI without a change in control - - - - - - (100) (100) Remuneration and redemption of hybrid bonds (equity) - - - - (23) (23) - (23) Other changes - - - (10) (92) (102) 107 5 Balance at June 30, 2025 3 10,934 (499) 186 10,728 21,352 156 21,508 . Balance at January 1, 2026 3 10,934 (1,208) 109 8,406 18,244 179 18,423 Total comprehensive income - - - 216 257 473 14 487 Dividend - (409) - - (215) (624) (50) (674) Stock options and share units granted - - - 35 - 35 - 35 Stock options and share units vested / canceled - - - (45) 45 - - - Reissued shares - - 43 - (43) - - - Repurchase own shares - - (290) - - (290) - (290) Cancellation of share capital - (1,364) 1,000 - 364 - - - Other changes - - - - (12) (12) 5 (7) Balance at June 30, 2026 3 9,161 (455) 315 8,802 17,826 148 17,974
Page 14
14/22 Condensed consolidated interim balance sheet at June 30 in € millions June 30 2026 December 31 2025 Assets Goodwill and intangible assets 15,235 15,384 Property, plant and equipment 4,316 4,174 Deferred tax assets 193 227 Share in associates and joint ventures 184 199 Derivatives 54 60 Other non-current assets 488 408 Non-current assets 20,470 20,452 Inventories 2,215 2,121 Trade receivables 2,184 1,841 Income tax receivables 76 153 Other receivables 95 105 Derivatives 33 41 Financial investments 47 121 Cash and cash equivalents 2,261 1,782 Sub-total 6,911 6,164 Assets held for sale 3,067 2,729 Current assets 9,978 8,893 Total assets 30,448 29,345 . Equity and liabilities Shareholders' equity 17,826 18,244 Non-controlling interest 148 179 Equity 17,974 18,423 Deferred tax liabilities 1,270 1,351 Employee benefit liabilities 201 193 Provisions 46 52 Borrowings 5,114 3,617 Derivatives 24 14 Other non-current liabilities 105 102 Non-current liabilities 6,760 5,329 Employee benefit liabilities 8 12 Provisions 62 51 Borrowings 1,651 1,660 Derivatives 30 14 Trade payables 1,732 1,481 Income tax payables 222 303 Other current liabilities 535 666 Sub-total 4,240 4,187 Liabilities held for sale 1,474 1,406 Current liabilities 5,714 5,593 Total equity and liabilities 30,448 29,345
Page 15
15/22 Condensed consolidated interim cash flow statement1 in € millions H1 2026 H1 2025 Cash and cash equivalents (at beginning of period) 1,782 2,667 Operating activities Net profit for the period² 221 541 Share of profit of associates and joint ventures 15 49 Income tax expenses 91 122 Profit before tax 327 712 Finance income and expense 80 74 Operating profit 407 786 Depreciation, amortization and impairments 473 601 EBITDA 880 1,387 Changes in working capital (257) (644) Income tax (212) (207) Other 86 (244) Cash provided by operating activities 497 292 of which provided by continuing operations 582 159 Investing activities Payments for intangible assets and property, plant and equipment (462) (401) Acquisition of businesses (4) (44) Disposal of businesses (64) 1,384 Proceeds from disposal of other non-current assets 11 34 Change in short-term financial investments 70 6 Interest received 16 20 Dividend received and capital (re)payments (24) (15) Other cash from / used in investing activities (4) (16) Cash used in investing activities (461) 968 Financing activities Dividends paid (674) (713) Interest paid (52) (35) Repurchase of shares (284) (405) Proceeds from / repayment of corporate bonds 1,492 239 Payment of lease liabilities (58) (53) Other cash from / used in financing activities 3 (73) Cash (used in) / from financing activities 427 (1,040) Change in cash and cash equivalents 463 220 Exchange differences relating to cash held 17 (66) Cash and cash equivalents at end of period (including cash classified as held for sale) at June 30 2,262 2,821 Reclassification to held for sale (1) - Cash and cash equivalents at end of period 2,261 2,821 1 The condensed consolidated interim cash flow statement includes an analysis of all cash flows in total, therefore including both continuing and discontinued operations. 2 Refers to net profit total Group, which includes both continuing and discontinued operations. Net profit of continuing operations is €225 million.
Page 16
16/22 Notes to the condensed consolidated interim financial statements Note 1 - General Information dsm-firmenich Group dsm-firmenich is domiciled in Switzerland with the seat of the principal in Kaiseraugst (Switzerland), listed on Euronext Amsterdam (DSFIR) and SIX Swiss Exchange (DSFIR). These condensed consolidated interim financial statements comprise DSM-Firmenich AG and its subsidiaries (the ‘Group’). Basis of preparation The accounting policies applied in these interim financial statements are the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 “Interim Financial Reporting” and should be read in conjunction with the accounting policies as included in the Integrated Annual Report 2025. New or amended IFRS that became effective on or after 1 January 2026 did not have a significant impact on the condensed consolidated interim financial statements of dsm-firmenich. Audit The condensed consolidated interim financial statements and other reported data in this press release have not been audited. Seasonality The Group operates in markets where generally no significant seasonal or cyclical variations in revenue are experienced during the financial year. However, in cases where businesses are significantly affected by seasonal or cyclical fluctuations in sales, this is discussed in the business review sections earlier in this report.
Page 17
17/22 Note 2 - Alternative performance measures In presenting and discussing dsm-firmenich’s financial position, operating results and net results, management uses certain Alternative performance measures not defined by IFRS. These Alternative performance measures (APMs) should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. The main APM adjustments to operating profit (EBIT) in the first half of 2026 are listed below: • Restructuring costs of €22 million, mainly related to the cost of current savings and restructuring programs • Other costs of €42 million, mainly related to litigation and claims The below table provides a reconciliation of the APMs to the most directly reconcilable IFRS metric for the first half of the reporting period. H1 2026 H1 2025 in € millions Continuing operations Total Group Continuing operations Total Group Operating profit (EBIT) 370 407 383 786 Depreciation, amortization and impairments 466 473 459 601 EBITDA 836 880 842 1,387 Acquisitions/divestments/integration - 22 36 (157) Restructuring 22 22 28 30 Other 42 43 - - Sub-total APM adjustments to EBITDA 64 87 64 (127) Adj. EBITDA 900 967 906 1,260 . Operating profit (EBIT) 370 407 383 786 APM adjustments to EBITDA 64 87 64 (127) Impairments of PPE and Intangible assets 1 8 3 21 Sub-total APM adjustments to operating profit (EBIT) 65 95 67 (106) Adj. operating profit (EBIT) 435 502 450 680 PPA adjustments 229 244 227 242 Core adj. operating profit (EBIT) 664 746 677 922 . Net profit 225 221 197 541 APM adjustments to operating profit (EBIT) 65 95 67 (106) APM adjustments to financial income and expense - 11 - - Income tax related to APM adjustments (14) (21) (13) (22) APM adjustments to share of the profit of associates/jointly controlled entities Sub-total APM adjustments 51 85 54 (128) Adj. Net profit 276 306 251 413 PPA adjustments 189 199 190 200 Core adj. net profit 465 505 441 613 Profit attributable to non-controlling interests (4) (9) (16) (31) Core adj. net profit available to holders of ordinary shares 461 496 425 582
Page 18
18/22 H1 2026 H1 2025 Continuing operations Total Group Continuing operations Total Group Earnings per share (EPS) Average number of ordinary shares outstanding (x million) 250.2 250.2 263.5 263.5 . x € million Net profit (loss) available to holders of ordinary shares 221 212 181 510 Adjusted net profit available to holders of ordinary shares 272 297 235 382 Core adj. net profit available to holders of ordinary shares 461 496 425 582 . in € EPS 0.88 0.85 0.69 1.94 Adj. EPS 1.09 1.19 0.89 1.45 Core adj. EPS 1.84 1.98 1.61 2.21 H1 2026 H1 2025 in € millions Continuing operations Continuing operations Adjusted EBITDA 900 906 Change working capital (191) (512) Capital expenditures (389) (315) Adj. gross operating free cash flow 320 79 H1 2026 H1 2025 Continuing Operations Total Group Continuing Operations Total Group in € million Adjusted Total Adjusted Total Adjusted Total Adjusted Total Net Sales 4,664 4,664 6,182 6,182 4,643 4,643 6,510 6,510 Gross margin 1,866 1,866 2,195 2,195 1,848 1,848 2,380 2,380 EBITDA 900 836 967 880 906 842 1,260 1,387 Depreciation & Amortization 465 466 465 473 456 459 580 601 EBIT 435 370 502 407 450 383 680 786 Financial income and expense (66) (66) (69) (80) (69) (69) (74) (74) Profit before inc. tax 369 304 433 327 381 314 606 712 Income tax expense (77) (63) (112) (91) (80) (67) (144) (122) Share profit and other results associates (16) (16) (15) (15) (50) (50) (49) (49) Group net profit 276 225 306 221 251 197 413 541 PPA adjustments 189 199 190 200 Core net profit 465 505 441 613
Page 19
19/22 Note 3 - Change in the scope of consolidation Assets and liabilities held for sale At the end of 2025, the assets and liabilities relating to the remaining ANH business were reclassified to held for sale based on its highly probable sale within the next 12 months. The impact of the reclassification of these activities on the dsm-firmenich consolidated balance sheet is presented in the following table. in € millions June 30 2026 December 31 2025 Assets Goodwill and intangible assets 133 119 Property, plant and equipment 497 439 Deferred tax assets 397 379 Prepaid pension costs - 2 Share in associates and joint ventures 28 25 Other non-current assets 45 40 Non-current assets 1,100 1,004 Inventories 1,141 1,042 Trade receivables 698 630 Income tax receivables 37 20 Other current receivables 80 22 Cash and cash equivalents 11 11 Current assets 1,967 1,725 Total assets held for sale 3,067 2,729 Liabilities Deferred tax liabilities 135 100 Employee benefit liabilities 197 209 Provisions 13 3 Borrowings 47 50 Other non-current liabilities 44 45 Non-current Liabilities 436 407 Employee benefit liabilities - 6 Provisions 4 61 Borrowings 89 1 Trade payables 790 720 Income tax payables 19 46 Other current liabilities 136 165 Current liabilities 1,038 999 Total liabilities held for sale 1,474 1,406 Total held for sale 1,593 1,323
Page 20
20/22 Note 4 – Segment Information Operating segments dsm-firmenich is organized into three distinct Business Units, which have been identified as the reportable operating segments of dsm-firmenich: • Perfumery & Beauty (P&B) creates premium scents with proven benefits, using the best and largest palette of natural, synthetic, and biotech ingredients. • Taste, Texture & Health (TTH) helps customers create food and beverage products that are delicious, nutritious, affordable, and sustainable. Providing enjoyment and nourishment for consumers, business success for customers, and better health for people and planet. • Health, Nutrition & Care (HNC) provides people a way to look after their health by adding critical nutrients to their diet. Driving medical innovation forward, speeding up recovery, and enhancing quality of life. Any consolidated activities outside the three reportable operating segments above are reported as the reportable segment ‘Corporate Activities’. These consist of corporate operating and service activities that are not further allocated to the operating segments. x € millions Perfumery & Beauty Taste, Texture & Health Health, Nutrition & Care Corporate Activities Total continuing operations Discontinued operations Total H1 2025 Net sales 1,919 1,629 1,042 53 4,643 1,867 6,510 Adj. EBITDA¹ 426 335 196 (51) 906 354 1,260 Adj. operating profit¹ 249 174 98 (71) 450 230 680 Adj. EBITDA margin (in %) 22.2 20.6 18.8 19.5 19.0 19.4 . H1 2026 Net sales 1,948 1,634 1,035 47 4,664 1,518 6,182 Adj. EBITDA¹ 424 321 206 (51) 900 67 967 Adj. operating profit¹ 237 153 113 (68) 435 67 502 Adj. EBITDA margin (in %) 21.8 19.6 19.9 19.3 4.4 15.6 1 A reconciliation between the Alternative performance measures (APMs) and the most directly reconcilable IFRS metric can be fo und in Note 2 to the Condensed consolidated interim financial statements. Geographical information Switzer- land Nether- lands Rest of EMEA North America Latin America China Rest of Asia Total FY 2025¹ Net sales (by destination) In € millions 214 302 3,098 2,353 857 671 1,539 9,034 In % 2% 3% 35% 26% 10% 7% 17% 100% . Workforce at period-end (headcount)² 3,678 1,763 8,437 4,204 3,577 3,324 3,567 28,550 Intangible assets and property, plant and equipment at year- end (carrying amount) 11,190 1,555 3,279 2,393 322 522 297 19,558 . H1 2026 Net sales (by destination) In € millions 121 148 1,465 1,161 463 379 927 4,664 In % 3% 3% 31% 25% 10% 8% 20% 100% . Workforce at period-end (headcount) 2,135 1,512 6,131 3,961 1,799 2,152 3,096 20,786 Intangible assets and property, plant and equipment at period- end (carrying amount) 12,314 1,537 2,665 2,307 142 336 250 19,551 1 The comparative information refers to full year 2025 2 Refers to Total Group, including discontinued operations
Page 21
21/22 Note 5 – Financial Instruments The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for the financial assets and financial liabilities measured at amortized cost if the carrying amount is a reasonable approximation of the fair value. For methods and assumptions used to determine the fair value as well as information on the fair value hierarchy used, please refer to the Integrated Annual Report 2025. in € millions Carrying amount Fair value¹ Amortized cost Fair value of hedging instr. Fair value through Profit & Loss Fair value Other Compreh. Income Total Level 1 Level 2 Level 3 Total Assets at December 31, 2025 Non-current derivatives - - 60 - 60 - 60 - 60 Other participating interests - - - 168 168 67 48 53 168 Non-current loans to associates and JVs 78 - - - 78 Other non-current receivables 111 - - - 111 Trade receivables 1,841 - - - 1,841 Other current receivables 73 - - - 73 Current derivatives - 31 10 - 41 - 41 - 41 Financial investments 121 - - - 121 Cash and cash equivalents 1,659 - 123 - 1,782 123 - - 123 Liabilities at December 31, 2025 Non-current borrowings (3,617) - - - (3,617) (3,136) - - (3,136) Non-current derivatives - - (14) - (14) - - (14) (14) Other non-current liabilities (102) - - - (102) Current borrowings (1,660) - - - (1,660) (1,486) - - (1,486) Current derivatives - (2) (12) - (14) - (14) - (14) Trade payables (1,481) - - - (1,481) Other current liabilities (291) - (57) - (348) - - (57) (57) Assets at June 30, 2026 Non-current derivatives - - 54 - 54 - 54 - 54 Other participating interests - - - 184 184 74 49 61 184 Non-current loans to associates and JVs 84 - - - 84 Other non-current receivables 107 - - - 107 Trade receivables 2,184 - - - 2,184 Other current receivables 95 - - - 95 Current derivatives - 9 24 - 33 - 33 - 33 Financial investments 47 - - - 47 Cash and cash equivalents 1,773 - 488 - 2,261 488 - - 488 Liabilities at June 30, 2026 Non-current borrowings (5,114) - - - (5,114) (4,628) - - (4,628) Non-current derivatives - - (24) - (24) - - (24) (24) Other non-current liabilities - - - - - Current borrowings (1,651) - - - (1,651) (1,494) - - (1,494) Current derivatives - (13) (17) - (30) - (30) - (30) Trade payables (1,732) - - - (1,732) Other current liabilities (161) - (62) - (223) - - (62) - 1 Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Other techniques for which all inputs that have a significant effect on the fair value are observable, either directly or indirectly Level 3: Techniques that use inputs that have a significant effect on the fair value that are not based on observable market data
Page 22
22/22 Note 6 – Related-party transactions dsm-firmenich purchased and sold goods and services to various related parties in the first half of 2026. dsm-firmenich has identified its key management personnel and its associates and joint ventures as related parties. Within dsm-firmenich, the members of the Board of Directors and the Members of the Executive Committee of dsm-firmenich meet the definition of key management personnel. There were no material changes in the related-party transactions in the first half year of 2026, compared to the transactions as included in the Integrated Annual Report 2025. Note 7 – Contingent Liabilities Compared to the situation as disclosed in its integrated annual report as at 31 December 2025, dsm-firmenich has not identified any changes to its contingent liabilities.